Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Net Income (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Net Income for 3 consecutive years, with -$36.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 25.99% to -$36.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$204.6 million, a 63.97% increase, with the full-year FY2025 number at -$204.6 million, up 63.97% from a year prior.
  • Net Income was -$36.6 million for Q4 2025 at Nuvation Bio, up from -$55.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$13.8 million in Q4 2023 to a low of -$462.5 million in Q2 2024.
  • A 3-year average of -$70.7 million and a median of -$38.9 million in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: tumbled 2140.76% in 2024, then skyrocketed 87.24% in 2025.
  • Nuvation Bio's Net Income stood at -$13.8 million in 2023, then plummeted by 258.63% to -$49.4 million in 2024, then grew by 25.99% to -$36.6 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Net Income are -$36.6 million (Q4 2025), -$55.8 million (Q3 2025), and -$59.0 million (Q2 2025).